Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Arm Phase II Study of the Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer "TrasTUCAN Study"

NCT05583110 is registered in ClinicalTrials.gov with Spanish Breast Cancer Research Group as lead sponsor.

NCT NCT05583110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05583110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Arm Phase II Study of the Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer "TrasTUCAN Study"
Lead sponsor
Spanish Breast Cancer Research Group
Phase
Phase 2
Overall status
Terminated
Start date
March 8, 2023
Completion date
May 30, 2025
Enrollment
13 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive metastatic breast cancer, locally advanced her2 positive breast carcinoma